Pfizer Inc. (NYSE:PFE) Stock Holdings Decreased by PFG Advisors

PFG Advisors lowered its stake in Pfizer Inc. (NYSE:PFE) by 3.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 21,771 shares of the biopharmaceutical company’s stock after selling 682 shares during the period. PFG Advisors’ holdings in Pfizer were worth $578,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of PFE. Swedbank AB grew its position in shares of Pfizer by 0.7% during the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after buying an additional 37,636 shares during the last quarter. United Bank grew its position in shares of Pfizer by 3.7% during the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock valued at $1,030,000 after buying an additional 1,277 shares during the last quarter. GSA Capital Partners LLP grew its position in shares of Pfizer by 87.6% during the 3rd quarter. GSA Capital Partners LLP now owns 32,786 shares of the biopharmaceutical company’s stock valued at $949,000 after buying an additional 15,310 shares during the last quarter. Curi RMB Capital LLC grew its position in shares of Pfizer by 4.7% during the 3rd quarter. Curi RMB Capital LLC now owns 55,770 shares of the biopharmaceutical company’s stock valued at $1,614,000 after buying an additional 2,487 shares during the last quarter. Finally, Oak Harbor Wealth Partners LLC boosted its stake in Pfizer by 3.3% during the 3rd quarter. Oak Harbor Wealth Partners LLC now owns 73,828 shares of the biopharmaceutical company’s stock valued at $2,137,000 after purchasing an additional 2,375 shares during the period. Institutional investors own 68.36% of the company’s stock.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.06% of the company’s stock.

Pfizer Stock Up 0.5 %

PFE stock opened at $25.74 on Friday. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The firm has a market cap of $145.85 billion, a PE ratio of 18.25, a P/E/G ratio of 0.64 and a beta of 0.61. The firm has a 50 day simple moving average of $26.24 and a 200 day simple moving average of $27.15. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the business earned $0.10 earnings per share. The business’s quarterly revenue was up 24.7% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on PFE shares. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Wednesday. Wolfe Research started coverage on shares of Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 target price for the company. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Finally, Bank of America reissued a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.